# US 2026/0265325 A1 · Interleukin-33 variants, compositions and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0265325 A1
- Document ID: US20260265325A1
- Status: Published application
- Kind: A1
- Application number: 19/676,080
- Filed: 2026-05-13
- Published: 2026-09-10
- Earliest claimed: 2023-11-15
- Assignees: Slate Bio, Inc.; University of Virginia Patent Foundation
- Applicants: Slate Bio, Inc.; University of Virginia Patent Foundation
- Inventors: Michelle SOLTERO HIGGIN; Rahul SHARMA
- Web page: https://patentgrep.com/patent/US20260265325A1

## CPC

- C07K 14/54: Interleukins [IL]
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 14/55: IL-2
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/31: fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides, among other things, improved interleukin-33 (IL-33) variants engineered for increased manufacturability and activity, for example, mutated at one or more of N60, C116, C97, C121 or C148 relative to a truncated IL-33. The present invention also provides a multifunctional fusion protein comprising an IL-33 variant associated with an IL-2 polypeptide and optionally, a half-life extension moiety. The present invention further provides compositions and methods for proliferation and activity of ST2+ regulatory T cells, for prophylaxis and treatment of autoimmune disease.

## Claims

### Claim 1

A recombinant human interleukin-33 (IL-33) variant comprising one, two, three, four or five amino acid substitutions at N60, C97, C116, C121, and C148, wherein the IL-33 has improved activity and/or manufacturability relative to wild-type IL-33.

### Claim 2

A recombinant human interleukin-33 (IL-33) variant comprising an amino acid substitution at N60 and any one of C97, C116, C121 or C148.

### Claim 3

A recombinant human interleukin-33 (IL-33) variant comprising an amino acid substitution C116F and an additional amino acid at any one of C97, C121 or C148.

### Claim 4

A recombinant human interleukin-33 (IL-33) variant comprising at least one amino acid substitution selected from N60S, N60D, N60T, N60A, N60Q, N60E C97G, C97A, C97V, C116A, C116F, C116Y, C121A, C121S, C148A, C148G, C148S, C148Y or C148N.

### Claim 5

The recombinant human IL-33 variant of any one of the preceding claims comprising the amino acid substitutions of C97G and C116F.

### Claim 6 (depends on 5)

The recombinant human IL-33 variant of claim 5, further comprising the amino acid substitutions of C148G.

### Claim 7 (depends on 6)

The recombinant human IL-33 variant of claim 6 further comprising the amino acid substitutions of C121S.

### Claim 8

The recombinant human IL-33 variant of any one of the preceding claims, wherein the IL-33 is truncated.

### Claim 9

The recombinant human IL-33 variant of any one of the preceding claims, wherein the polypeptide comprises the sequence of any one of SEQ ID NOs: 2-8, and SEQ ID NOs: 82-83.

### Claim 10

A fusion protein comprising IL-33 of any one of the preceding claims.

### Claim 11 (depends on 10)

The fusion protein of claim 10, further comprising IL-2.

### Claim 12

The fusion protein of any one of the preceding claims, further comprising a half-life extension moiety.

### Claim 13

A multifunctional fusion protein comprising:
an IL-2 polypeptide,
an IL-33 polypeptide, and
a half-life extension moiety,
wherein the half-life extension moiety is located at the N-terminus or C-terminus of the fusion protein.

### Claim 14

A multifunctional fusion protein comprising:
an IL-2 polypeptide,
an IL-33 polypeptide, and
a half-life extension moiety,
wherein the half-life extension moiety is not an Fc domain of IgG.

### Claim 15

The multifunctional fusion protein of any one of the preceding claims, wherein the IL-33 polypeptide is a variant wherein the variant has improved activity and/or manufacturability relative to wild-type IL-33.

### Claim 16

The multifunctional fusion protein of any one of the preceding claims, comprising one, two, three, four or five amino acid substitutions at N60, C97, C116, C121, and C148.

### Claim 17 (depends on 13, 14)

The multifunctional fusion protein of any one of claim 13 or 14, comprising an amino acid substitution at N60 and any one of C97, C116, C121, or C148.

### Claim 18 (depends on 13, 14)

The multifunctional fusion protein of any one of claim 13 or 14, comprising an amino acid substitution at C116F and an additional amino acid at any one of C97, C121, or C148.

### Claim 19 (depends on 14, 15)

The multifunctional protein of any one of claim 14 or 15, comprising at least one amino acid substitution selected from N60S, N60D, N60A, N60T, N60Q, N60E C97G, C97A, C97V, C116A, C116F, C116Y, C121A, C121S, C148A, C148G, C148S, C148Y or C148N.

### Claim 20

The multifunctional protein of any one of the preceding claims, comprising the amino acid substitutions of C97G and C116F.

### Claim 21 (depends on 20)

The multifunctional protein of claim 20, further comprising the amino acid substitution of C148G.

### Claim 22 (depends on 21)

The multifunctional protein of claim 21, further comprising the amino acid substitution of C121S.

### Claim 23

The multifunctional fusion protein of any one of the preceding claims, wherein the IL-33 is truncated.

### Claim 24

The multifunctional fusion protein of any one of the preceding claims, wherein the IL-33 polypeptide comprises the sequence of any one of SEQ ID NO: 2-8, and SEQ ID NOs: 82-83.

### Claim 25

The multifunctional fusion protein of any one of the preceding claims, wherein the IL-2 polypeptide is a variant IL-2.

### Claim 26

The multifunctional fusion protein of any one of the preceding claims, wherein the IL-2 polypeptide comprises N88R, N88S, C125S, V69A or Q74P.

### Claim 27

The multifunctional fusion protein of any one of the preceding claims, wherein the half-life extension moiety is selected from the group consisting of monomethoxy poly-ethylene glycol (PEG), albumin, transferrin, Fc domain of IgG, highly sialylated peptide, XTEN, V-P-G-x-G (ELP), proline-alanine-serine (PAS) polymer, homo amino acid polymer (HAP) and gelatin-like protein (GLK).

### Claim 28 (depends on 27)

The PEG of claim 27, wherein the PEG is linear chain or branched chain.

### Claim 29 (depends on 27)

The multifunctional fusion protein of claim 27, wherein the albumin is human serum albumin (HSA).

### Claim 30 (depends on 27)

The multifunctional fusion protein of claim 27, wherein the highly sialylated peptide is carboxy terminal peptide (CTP) consisting of the sequence of FQSSSS* KAPPPS*LPSPS*RLPGPS*DTPILPQ (SEQ ID NO: 51).

### Claim 31 (depends on 27)

The multifunctional fusion protein of claim 27, wherein the homo amino acid polymer consists of glycine.

### Claim 32 (depends on 27)

The multifunctional fusion protein of claim 27, wherein the Fc domain comprises 90% identity to SEQ ID NO: 54.

### Claim 33 (depends on 27)

The multifunctional fusion protein of claim 27, wherein the Fc domain comprises 100% identity to the wild-type sequence of SEQ ID NO: 54.

### Claim 34 (depends on 27)

The multifunctional fusion protein of claim 27, wherein the Fc domain comprises one or more mutations that reduce effector function.

### Claim 35 (depends on 27)

The multifunctional fusion protein of claim 27, wherein the one or more mutations are selected from N297A, N297Q, N297G, L234A, L235E, G237A, P238S, H268Q, H268A, V309L, A330S and P331S.

### Claim 36

The multifunctional fusion protein of any one of the preceding claims, wherein the IL-2 and IL-33 polypeptides are 10 to 100 angstrom units (Å) apart.

### Claim 37

The multifunctional fusion protein of any one of the preceding claims, wherein the multifunctional protein further comprises a linker.

### Claim 38 (depends on 37)

The multifunctional fusion protein of claim 37, wherein the linker is a peptide linker or a chemical linker.

### Claim 39 (depends on 37)

The multifunctional fusion protein of claim 37, wherein the linker comprises a sequence of GGGGS (SEQ ID NO: 29) or GGGGSGGGGSGGGGS (SEQ ID NO: 30).

### Claim 40

The multifunctional fusion protein of any one of the preceding claims, further comprising a tag at the N-terminus or C-terminus.

### Claim 41 (depends on 40)

The multifunctional fusion protein of claim 40, wherein the tag is a Flag tag.

### Claim 42

The multifunctional fusion protein of any one of the preceding claims comprising the sequence of any one of SEQ ID NO: 58-79.

### Claim 43

The multifunctional fusion protein of any one of the preceding claims, wherein the fusion protein is lyophilized.

### Claim 44

A polynucleotide encoding the IL-33 polypeptide or the multifunctional fusion protein of any one of the preceding claims.

### Claim 45 (depends on 44)

A vector comprising the polynucleotide of claim 44.

### Claim 46 (depends on 45)

The vector of claim 45, wherein the vector is a viral vector or a non-viral vector.

### Claim 47 (depends on 46)

The vector of claim 46, wherein the viral vector is an adeno-associated virus vector, an adenovirus vector or a lentivirus vector.

### Claim 48 (depends on 44, 45, 46, 47)

An engineered host cell comprising the polynucleotide of claim 44 or the vector of claims 45 to 47.

### Claim 49 (depends on 48)

The engineered cell of claim 48, wherein the cell is a mammalian cell.

### Claim 50 (depends on 48)

The engineered cell of claim 48, wherein the cell is a bacterial cell.

### Claim 51 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A microparticle comprising the polynucleotide of claim 44 or the multifunctional fusion protein of any one of claims 11-43.

### Claim 52 (depends on 51)

The microparticle of claim 51, wherein the microparticle is a liposome, extracellular vesicle or a lipid nanoparticle.

### Claim 53

A pharmaceutical composition comprising the multifunctional fusion protein of any one of the preceding claims.

### Claim 54 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 48, 49, 50, 51)

A method of treating autoimmune disease, the method comprising administering to a subject in need thereof a therapeutically effective dose of the multifunctional fusion protein of any one of claims 11-43 or the pharmaceutical composition of claim 51 or the engineered cell of any one of claims 48-50.

### Claim 55

A method of treating an autoimmune disease, the method comprising administering to a subject in need thereof a therapeutically effective dose of a multifunctional fusion of an IL-2 polypeptide, an IL-33 polypeptide, and a half-life extension moiety, wherein the half-life extension moiety is located at the N-terminus or C-terminus of the fusion protein.

### Claim 56 (depends on 54, 55)

The method of any one of claim 54 or 55, wherein the administration is subcutaneous, intramuscular or intravenous.

### Claim 57 (depends on 56)

The method of claim 56, wherein the administration is subcutaneous.

### Claim 58

The method of any one of the preceding claims, wherein the administration stimulates proliferation and/or activation of immune cells.

### Claim 59

The method of any one of the preceding claims, wherein the immune cells are ST2+ cells, Foxp3-ST2+ and Foxp3-ST2-Tr1 cells, Th3 cells, ILC2, macrophages, MDSCs, regulatory B cells, B1B cells, or tolerogenic dendritic cells.

### Claim 60 (depends on 59)

The method of claim 59, wherein the ST2+ cells are ST2+ T regulatory cells, tissue resident ST2+ cells or a combination of tissue resident ST2+ and CD25bright cells.

### Claim 61 (depends on 60)

The method of claim 60, wherein the proliferation and/or activation of ST2+ T regulatory cells is at least greater than 100-fold relative to a control.

### Claim 62

The method of any one of the preceding claims, wherein the administration leads to coexpression of IL-2 and IL-33 in the same tissue.

### Claim 63

The method of any one of the preceding claims, wherein IL-2 and IL-33 synergistically show increased potency and/or increased avidity relative to IL-2 or IL-33 alone.

### Claim 64

The method of any one of the preceding claims, wherein administration increases local immune tolerance in a tissue microenvironment.
